Nature Publishing Group, publisher of Nature, and other science journals and reference works NATURE.COM NATURE NEWS NATUREJOBS NATUREEVENTS ABOUT NPG
Help Nature.com site index  
The Pharmacogenomics Journal
SEARCH     advanced search my account e-alerts subscribe register
Journal home
Advance online publication
Current issue
Archive
Press releases
For authors
For referees
Contact editorial office
About the journal
For librarians
Subscribe
Advertising
naturereprints
Contact NPG
Customer services
Site features
NPG Subject areas
Access material from all our publications in your subject area:
Biotechnology Biotechnology
Cancer Cancer
Chemistry Chemistry
Dentistry Dentistry
Development Development
Drug Discovery Drug Discovery
Earth Sciences Earth Sciences
Evolution & Ecology Evolution & Ecology
Genetics Genetics
Immunology Immunology
Materials Materials Science
Medical Research Medical Research
Microbiology Microbiology
Molecular Cell Biology Molecular Cell Biology
Neuroscience Neuroscience
Pharmacology Pharmacology
Physics Physics
Browse all publications
 
2002, Volume 2, Number 5, Pages 284-292
Table of contents    Previous  Abstract  Next   Full text  PDF
Clinical Implication
Elements of informed consent for pharmacogenetic research; perspective of the pharmacogenetics working group
D C Anderson1, B Gomez-Mancilla1, B B Spear2, D M Barnes2, K Cheeseman3, P M Shaw4, J Friedman4, A McCarthy5, C Brazell5, S C Ray6, D McHale7, L Hashimoto8, R Sandbrink9, M L Watson10, R A Salerno11, N Cohen12 and C E Lister13 on behalf of The Pharmacogenetics Working Group

1Pharmacia Corporation, Pharmacogenomics, Kalamazoo, MI, USA

2Abbott Laboratories, Pharmacogenetics, Abbott Laboratories, Abbott Park, IL, USA

3Astra-Zeneca, Experimental Medicine, Loughborough, UK

4Bristol-Myers Squibb, Pharmacogenomics & Human Genetics, Princeton, NJ, USA

5GlaxoSmithKline, Genetics Research, Greenford, Middlesex, UK

6GlaxoSmithKline, Genetics Research, Research Triangle Park, NC, USA

7Pfizer, Global Research & Development, Sandwich Laboratories, Sandwich, Kent, UK

8F Hoffmann-La Roche Ltd., Roche Genetics, Basel, Switzerland

9Schering AG, SBU Specialized Therapeutics, Berlin, Germany

10Merck & Co., Clinical Genomics, West Point, PA, USA

11Wyeth Research, Wyeth Pharmaceuticals, Inc., Worldwide Regulatory Affairs, St. Davids, PA, USA

12Johnson & Johnson Pharmaceutical Research and Development, Pharmacogenomics, Raritan, NJ, USA

13Covington and Burling, London, UK

Correspondence to: DC Anderson, Pharmacia Corporation, 7000 Portage Rd, 8297-24-108A, Kalamazoo, MI 49001-0199, USA. E-mail: donald.c.anderson@pharmacia.com

Members of the Pharmacogenetics Working Group include: Abbott Laboratories, Amgen, AstraZeneca, Aventis, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Organon, Pfizer, Pharmacia Corporation, F Hoffmann-La Roche Ltd., Schering AG, Schering-Plough, and Wyeth Research.

Abstract

The Pharmacogenomics Journal (2002) 2, 284-292. doi:10.1038/sj.tpj.6500131

2002, Volume 2, Number 5, Pages 284-292
Table of contents    Previous  Abstract  Next   Full text  PDF
Privacy Policy © 2002 Nature Publishing Group